Cargando…

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults

Mostrar otras versiones (1)

BACKGROUND: The Uganda Ministry of Health issued restrictive guidelines on the use of dolutegravir (DTG) in persons stratified to have a heightened risk of diabetes mellitus. This followed multiple reports of persons with HIV (PWH) presenting with accelerated hyperglycemia after a few weeks to month...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mulindwa, Frank, Castelnuovo, Barbara, Brusselaers, Nele, Nabwana, Martin, Bollinger, Robert, Laker, Eva, Kiguba, Ronald, Schwarz, Jean-Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371155/ https://www.ncbi.nlm.nih.gov/pubmed/37502917 http://dx.doi.org/10.21203/rs.3.rs-3175598/v1

Ejemplares similares

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
por: Mulindwa, Frank, et al.
Publicado: (2023)

Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks
por: Mulindwa, Frank, et al.
Publicado: (2023)

Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir
por: Mulindwa, Frank, et al.
Publicado: (2023)

Implementation of longitudinal insulin kinetic studies in busy field settings in Uganda: experience from the “glucose metabolism changes in Ugandan HIV patients on dolutegravir based anti-retroviral therapy” (GLUMED study)
por: Mulindwa, Frank, et al.
Publicado: (2023)

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? A case report
por: Mulindwa, Frank, et al.
Publicado: (2023)

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
por: Mulindwa, Frank, et al.
Publicado: (2023)

Association between integrase strand transfer inhibitor use with insulin resistance and incident diabetes mellitus in persons living with HIV: a systematic review and meta-analysis
por: Mulindwa, Frank, et al.
Publicado: (2023)

Association between integrase strand transfer inhibitor (INSTIs) use with insulin resistance and incident diabetes mellitus in persons living with HIV: A systematic review and meta-analysis protocol
por: Mulindwa, Frank, et al.
Publicado: (2022)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2022)

Prevalence of Cardiometabolic Disease Risk Factors in People With HIV Initiating Antiretroviral Therapy at a High-Volume HIV Clinic in Kampala, Uganda
por: Amutuhaire, Willington, et al.
Publicado: (2023)

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials
por: Raffi, François, et al.
Publicado: (2015)

Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
por: Cahn, Pedro, et al.
Publicado: (2017)

Herbal medicine use and linked suspected adverse drug reactions in a prospective cohort of Ugandan inpatients
por: Kiguba, Ronald, et al.
Publicado: (2016)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
por: Capetti, Amedeo F., et al.
Publicado: (2017)

Incidence, risk factors and risk prediction of hospital-acquired suspected adverse drug reactions: a prospective cohort of Ugandan inpatients
por: Kiguba, Ronald, et al.
Publicado: (2017)

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda
por: Twimukye, Adelline, et al.
Publicado: (2021)

Poor immunological recovery among severely immunosuppressed antiretroviral therapy-naïve Ugandans
por: Nanzigu, Sarah, et al.
Publicado: (2013)

Weight gain in patients starting Dolutegravir-based ART according to baseline CD4 count after 48 weeks of follow up
por: Cardoso-Neto, Érico C., et al.
Publicado: (2023)

Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups
por: Rawlings, M Keith, et al.
Publicado: (2022)

Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study
por: Zakumumpa, Henry, et al.
Publicado: (2022)

Factors associated with uptake of contraceptives among HIV positive women on dolutegravir based anti-retroviral treatment-a cross sectional survey in urban Uganda
por: Mbabazi, Leah, et al.
Publicado: (2022)

Perceptions of doctors and nurses at a Ugandan hospital regarding the introduction and use of the South African Triage Scale
por: Mulindwa, Francis, et al.
Publicado: (2016)

48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort
por: Cabello-Ubeda, Alfonso, et al.
Publicado: (2022)

Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks
por: Jörimann, Lisa, et al.
Publicado: (2023)

Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study
por: Zakumumpa, Henry, et al.
Publicado: (2021)

Drug-related pellagra in a Ugandan woman on isoniazid preventative therapy
por: Coates, Sarah J., et al.
Publicado: (2020)

Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks
por: Quercia, Romina, et al.
Publicado: (2015)

Nasopharyngeal carriage rate of Streptococcus pneumoniae in Ugandan children with sickle cell disease
por: Kateete, David P, et al.
Publicado: (2012)

1582. Dolutegravir/Rilpivirine STR Switch Study in Persons with HIV-1 and Chronic Kidney Disease: 48-week Assessment of Viral Suppression, Treatment Adherence and Quality of Life
por: Kwakwa, Helena, et al.
Publicado: (2023)

48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-Analysis
por: Patel, Dipen A., et al.
Publicado: (2014)

48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
por: Yazdanpanah, Y, et al.
Publicado: (2014)

Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL’HIV trial
por: Sculier, Delphine, et al.
Publicado: (2020)

Translating medical device innovations to market - a Ugandan perspective
por: Matovu, Brian, et al.
Publicado: (2023)

Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)
por: De Miguel, Rosa, et al.
Publicado: (2020)

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
por: Laker, Eva Agnes Odongpiny, et al.
Publicado: (2019)

Common Coinfections of Giardia intestinalis and Helicobacter pylori in Non-Symptomatic Ugandan Children
por: Ankarklev, Johan, et al.
Publicado: (2012)

Prevalence of Helicobacter pylori in HIV-infected, HAART-naïve Ugandan children: a hospital-based survey
por: Hestvik, Elin, et al.
Publicado: (2011)

The promise of paediatric dolutegravir
por: Golin, Rachel, et al.
Publicado: (2021)

Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine
por: Wohl, David, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0tfla9smrbpu0gi55csse1ap71